Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine.
Sumatriptan nasal powder delivered by a breath powered delivery device (ONZETRA®Xsail®) is indicated for the acute treatment of migraine with or without aura in adults. This narrative review discusses the clinical use of sumatriptan nasal powder in this population and summarizes its pharmacological properties. In migraineurs, sumatriptan nasal powder treatment was associated with significantly greater rates of pain relief than placebo from 0.5-2 h postdose after a single treatment in the phase 3 TARGET trial, with these benefits sustained at 24 and 48 h postdose. Compared with oral sumatriptan, sumatriptan nasal powder was associated with significantly faster pain relief during the first 30 min after treatment in the phase 3 COMPASS trial assessing the treatment of up to five migraines in adults and better pain relief and pain freedom from 15 min to 1.5 h postdose. However, there were no between-group differences in pain relief at subsequent timepoints up to 48 h postdose. Sumatriptan nasal powder was generally well tolerated, with the majority of adverse events administration-site related and mild or moderate in severity. In conclusion, sumatriptan nasal powder is an effective and generally well tolerated treatment of migraine. With its novel breath powered nasal delivery resulting in a faster onset of action than oral sumatriptan, sumatriptan nasal powder provides a useful new option for the acute treatment of migraine with and without aura in adults.
Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. demail@springer.com.
Zaina T
ZT
Al-Salama
Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
Lesley J
LJ
Scott
D000281:Administration, Intranasal; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D011208:Powders / Q000008:administration & dosage*; D018170:Sumatriptan / Q000008:administration & dosage*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
D011208:Powders; D014662:Vasoconstrictor Agents; D018170:Sumatriptan
Headache. 2001 Jul-Aug;41(7):646-57
11554952
Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6
25662743
Curr Vasc Pharmacol. 2003 Mar;1(1):71-84
15320857
Drugs. 1998 Jun;55(6):889-922
9617601
Expert Opin Drug Deliv. 2015;12(9):1565-77
26119828
Headache. 2007 Apr;47(4):475-9
17445096
Cephalalgia. 2013 Jul;33(9):629-808
23771276
Drugs. 2012 Dec 3;72(17):2187-205
23116251
Headache. 2013 Sep;53(8):1323-33
23992438
Headache. 2015 May;55(5):621-35
25941016
Cephalalgia. 2010 Aug;30(8):933-42
20656704
Headache. 2015 Jan;55(1):88-100
25355310
Drugs. 2010 Aug 20;70(12):1505-18
20687618
Expert Opin Pharmacother. 2015;16(13):2039-51
26255952
Headache. 2015 Jan;55(1):3-20
25600718
Headache. 2009 Apr;49(4):498-508
19245386